<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04481230</url>
  </required_header>
  <id_info>
    <org_study_id>2020-000495-37</org_study_id>
    <nct_id>NCT04481230</nct_id>
  </id_info>
  <brief_title>Assessment of 99mTc-NTP 15-5 Uptake on Cartilage, a New Proteoglycan Tracer</brief_title>
  <acronym>CARSPECT</acronym>
  <official_title>Assessment of 99mTc-NTP 15-5 Uptake on Cartilage, a New Proteoglycan Tracer: Phase I Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Jean Perrin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Jean Perrin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a phase I clinical trial aimed to determine the recommended dose of 99mTc-NTP
      15-5 to obtain the best tracer joints contrast on images without any toxicity.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>dose escalation model</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>determination of the recommended dose of 99mTc-NTP 15-5 to obtain the best tracer joints contrast on images without any toxicity</measure>
    <time_frame>Imaging at Day 0 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours post-injection)</time_frame>
    <description>defined as the dose from which 100% of patients will present a score 3 (semi-quantitative visual scale on whole body imaging) in at least 80% of healthy joints visualized on scintigraphies performed 2 h or less post-injection and without dose-limiting toxicity (DLT).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>dose-limiting toxicity (DLT)</measure>
    <time_frame>1 week after injection of the 99mTc-NTP 15-5 (Day 0)</time_frame>
    <description>defined as any grade 3-4 toxicity according to the NCI-CTCAE (version 4.03)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>3D quantification analysis</measure>
    <time_frame>imaging at Day 0, 30 minutes, 2 hours, 4 hours, 6-8 hours after injection of the 99mTc-NTP 15-5</time_frame>
    <description>TEMP Volumetric regions of interest (VOI) will be centered on cartilaginous zones, and on the corresponding bony diaphyses or vertebral body or the adjacent muscles. The articular uptake of 99mTc NTP-15-5 will thus be normalized to bone or muscle uptake.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of 99mTc-NTP 15-5 (frequence of adverse events)</measure>
    <time_frame>1 week after injection of the 99mTc-NTP 15-5 (Day 0)</time_frame>
    <description>according to the NCI-CTCAE (version 4.03)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biodistribution of 99mTc-NTP 15-5</measure>
    <time_frame>imaging at Day 0, 30 minutes, 2 hours, 4 hours, 6-8 hours after injection of the 99mTc-NTP 15-5</time_frame>
    <description>evaluated by measuring the percentage of injected activity of 99mTc-NTP 15-5 fixed on the target organs and on the pathological joints or healthy joints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of 99mTc-NTP 15-5 by assessment of Area Under the Curve (AUC)</measure>
    <time_frame>at Day 0 during the first 8 hours after injection of the 99mTc-NTP 15-5</time_frame>
    <description>radiation counting on whole blood and on plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of 99mTc-NTP 15-5 by assessment of Maximum Concentration (Cmax)</measure>
    <time_frame>at Day 0 during the first 8 hours after injection of the 99mTc-NTP 15-5</time_frame>
    <description>radiation counting on whole blood and on plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of 99mTc-NTP 15-5 by assessment of the time take to reach Cmax (Tmax)</measure>
    <time_frame>at Day 0 during the first 8 hours after injection of the 99mTc-NTP 15-5</time_frame>
    <description>radiation counting on whole blood and on plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary elimination of 99mTc-NTP 15-5</measure>
    <time_frame>at Day 0 during the first 8 hours after injection of the 99mTc-NTP 15-5</time_frame>
    <description>by counting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosimetry</measure>
    <time_frame>imaging at Day 0, 30 minutes, 2 hours, 4 hours, 6-8 hours after injection of the 99mTc-NTP 15-5</time_frame>
    <description>measurement of the absorbed dose per organ will be evaluated by quantitative analysis.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>99mTc-NTP 15-5 (level 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>99mTc-NTP 15-5 at a diagnostic activity of 5 MBq/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>99mTc-NTP 15-5 (level 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>99mTc-NTP 15-5 at a diagnostic activity of 10 MBq/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>99mTc-NTP 15-5 (level 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>99mTc-NTP 15-5 at a diagnostic activity of 15 MBq/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>99mTc-NTP 15-5 at a diagnostic activity of 5 MBq/kg</intervention_name>
    <description>1 intravenous injection of 99mTc-NTP 15-5 at a diagnostic activity of 5 MBq/kg (D0)</description>
    <arm_group_label>99mTc-NTP 15-5 (level 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>99mTc-NTP 15-5 at a diagnostic activity of 10 MBq/kg</intervention_name>
    <description>1 intravenous injection of 99mTc-NTP 15-5 at a diagnostic activity of 10 MBq/kg (D0)</description>
    <arm_group_label>99mTc-NTP 15-5 (level 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>99mTc-NTP 15-5 at a diagnostic activity of 15 MBq/kg</intervention_name>
    <description>1 intravenous injection of 99mTc-NTP 15-5 at a diagnostic activity of 15 MBq/kg (D0)</description>
    <arm_group_label>99mTc-NTP 15-5 (level 3)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Inclusion criteria specific to group 1:

        - Patient with painful post-traumatic unilateral osteoarthritis of the knee as femorotibial
        pattern (except femoropatellar) defined by a radiographic score of 0/1 from Kellgren /
        Lawrence and an average WOMAC score&gt; or equal to 4 and by minor disorders at MRI (MOCART
        2.0 score&gt; 70).

        Inclusion criteria specific to group 2:

          -  Patient with non-metastatic breast cancer, hormone receptor positive, HER2 negative,
             with indication for adjuvant therapy with aromatase inhibitor; treatment not yet
             started.

          -  Age &lt;60 years

        Common inclusion criteria:

          -  Patient with at least 31 healthy joints (based on clinical assessment)

          -  signed written informed consent.

          -  Affiliation to a health insurance scheme.

          -  For women of childbearing age : negative serum pregnancy test at inclusion (less than
             7 days prior injection of 99mTc-NTP 15-5).

          -  Willing and able to comply with study visits, treatment, exams and the protocol.

        Exclusion Criteria:

          -  Patients &lt;18 years of age.

          -  Pregnant or lactating patient.

          -  BMI&gt; 30

          -  History of known allergy to excipients contained in the solution of 99mTc-NTP 15-5

          -  Chronic inflammatory rheumatism (rheumatoid arthritis, spondyloarthropathy, psoriatic
             arthritis, etc.) diffuse arthritis (at least 3 joints affected), autoimmune
             connectivitis, fibromyalgia.

          -  Known chronic joint pathology: osteoarthritis affecting at least 3 joints, autoimmune
             disease, inflammatory rheumatism (except unilateral knee arthritis).

          -  Persons deprived of their liberty, under guardianship / curatorship, or safeguard of
             justice.

          -  Treatment with NSAIDs or cessation of less than 48 h.

          -  Inability to comply with medical requirement / follow-up of the trial for geographic,
             family, social or psychological reasons. These conditions should be discussed with the
             patient before registration in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florent CACHIN, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Jean Perrin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Florent CACHIN, Pr</last_name>
    <phone>33473278089</phone>
    <email>florent.cachin@clermont.unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Florent CACHIN, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Florent CACHIN, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Sylvain MATHIEU, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sylvain MATHIEU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 2, 2020</study_first_submitted>
  <study_first_submitted_qc>July 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2020</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cartilage</keyword>
  <keyword>proteoglycan tracer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

